Renaissance Capital logo

CELC News

US IPO Weekly Recap: An active week as 7 IPOs average 16% pop

CELC

Seven deals raised a combined $1.2 billion this past week and first day returns averaged 16%. Performance was particularly strong for the healthcare space; Chinese cancer biotech Zai Lab led the pack, returning 55% on its first day,...read more

Tissue test: Celcuity prices upsized IPO above the midpoint at $9.50 to raise $23 million

Celcuity logo

Celcuity, which is developing live cell diagnostic tests for cancer patients, raised $22.8 million by offering 2.4 million shares at $9.50, within the range of $8 to $10. It originally filed to offer 2.0 million shares. At $9.50, the pre-revenue company commands...read more

US IPO Week Ahead: Most active week of the quarter with 7 IPOs, led by Alibaba-backed Best

BSTI

Seven deals are on the IPO calendar to raise a combined $1.6 billion in the week ahead. Chinese logistics provider Best leads the pack with an $869 million offering (the largest IPO of Q3), followed by leading Latin American...read more

Pre-revenue diagnostics company Celcuity sets terms for $18 million IPO

Celcuity logo

Celcuity, which is developing live cell diagnostic tests for cancer patients, announced terms for its IPO on Thursday. The Minneapolis, MN-based company plans to raise $18 million by offering 2 million shares at a price range of $8 to $10. At the midpoint...read more